qz
How Will Skyrizi and Rinvoq Shape AbbVie's Q1 Immunology Sales?

ABBV heads into Q1 earnings with Skyrizi and Rinvoq in focus as Humira declines, while growth from new indications and market share gains is under watch. [...]

Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

qz
AbbVie beat earnings expectations and raised its outlook as newer drugs offset Humira's decline

Skyrizi and Rinvoq together generated more than $6.6 billion in quarterly sales, far outpacing Humira's $688 million [...]

Match Score: 101.57

Destination
The best gaming mouse in 2025

No gaming mouse will magically stop you from getting destroyed in Counter-Strike or Call of Duty, but the right pick can give you a greater sense of control while making your downtime more comfortable [...]

Match Score: 86.51

qz
AbbVie is buying an eczema and asthma drug developer for nearly $11 billion

The all-cash deal gives AbbVie access to zumilokibart, an experimental drug that could rival Dupixent in treating atopic dermatitis [...]

Match Score: 54.93

Destination
Engadget Podcast: iPhone 16e review and Amazon's AI-powered Alexa+

The keyword for the iPhone 16e seems to be "compromise." In this episode, Devindra chats with Cherlynn about her iPhone 16e review and try to figure out who this phone is actually for. Also, [...]

Match Score: 49.70

blogspot
How I Get Free Traffic from ChatGPT in 2025 (AIO vs SEO)

Three weeks ago, I tested something that completely changed how I think about organic traffic. I opened ChatGPT and asked a simple question: "What's the best course on building SaaS with Wor [...]

Match Score: 48.28

Destination
Engadget's favorite games of 2025

From indies like Silksong, to AAAs like Ghost of Yotei, and everything in between, 2025 truly had it all, and is likely to go down in the history books as one of the best years in gaming. But these ar [...]

Match Score: 44.69

qz
AbbVie beat profit estimates but cut its forecast — and the stock sank

The drugmaker beat second-quarter estimates on strong immunology sales but lowered its full-year adjusted earnings outlook by 14 cents a share [...]

Match Score: 41.70

qz
Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy

JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure. [...]

Match Score: 36.94

Destination
All the tech and gadgets announced at CES 2026

It's the first week of a new year and there's no time for the tech world to slowly ease back into things following the holidays. That's because CES 2026 is in full swing, with all manne [...]

Match Score: 33.47